

## ASX Announcement

29 April 2025

## ReNerve Ltd – Quarterly Report Webinar

Wednesday, 7 May 2025 at 11:00am (AEST)

ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”) is pleased to invite shareholders and prospective investors to an investor webinar, where ReNerve CEO, Dr Julian Chick will provide an update to accompany the recent Quarterly Report.

**Event Details:** ReNerve Limited (ASX:RNV) Investor Webinar

**Date/Time:** Wednesday 7 May 2025,  
11:00am AEST (9:00am AWST)

**Presenter:** Dr Julian Chick, CEO of ReNerve Ltd

**Registration:** <https://bit.ly/RNV-Q3-FY2025>



During the webinar, Dr Chick will provide a Company update for the Quarter ended 31 March 2025, as well as an overview for the remainder of CY2025.

This will be followed by a brief live Q&A session, where Dr Chick will be answering questions that attendees are able to submit ahead of time, or using the live Q&A feature on Zoom.

Attendees are invited to submit questions prior to the webinar to [info@janemorganmanagement.com.au](mailto:info@janemorganmanagement.com.au)

**This announcement has been approved for release by the Company’s Board of Directors.**

**For further information and enquiries, please contact:**

**Dr Julian Chick**  
CEO  
ReNerve Ltd  
+61 (0) 417 137 291  
[info@renerve.com.au](mailto:info@renerve.com.au)

**Jane Morgan**  
Investor & Media Relations  
Jane Morgan Management  
+61 (0) 405 555 618  
[jm@janemorganmanagement.com.au](mailto:jm@janemorganmanagement.com.au)



## About ReNerve™ Limited

ReNerve Limited (ASX:RNV) is an Australian-based biotechnology company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering products that seek to address significant unmet needs in peripheral nerve damage patients – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry's Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff™.